H
Henrik S. Rasmussen
Researcher at GenVec
Publications - 33
Citations - 2324
Henrik S. Rasmussen is an academic researcher from GenVec. The author has contributed to research in topics: Vascular disease & Coronary artery disease. The author has an hindex of 18, co-authored 33 publications receiving 2243 citations. Previous affiliations of Henrik S. Rasmussen include University of Kentucky.
Papers
More filters
Journal ArticleDOI
Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease A Phase II Randomized, Double-Blind, Controlled Study of Adenoviral Delivery of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Claudication
Sanjay Rajagopalan,Emile R. Mohler,Robert J. Lederman,Farrell O. Mendelsohn,Jorge F. Saucedo,Corey K. Goldman,John Blebea,Jennifer Macko,Paul D. Kessler,Henrik S. Rasmussen,Brian H. Annex +10 more
TL;DR: A single unilateral intramuscular administration of AdVEGF121 was not associated with improved exercise performance or quality of life in this study, and this study does not support local delivery of single-dose VEGF121 as a treatment strategy in patients with unilateral PAD.
Journal ArticleDOI
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
D J Stewart,J D Hilton,J M O Arnold,J Gregoire,A Rivard,Stephen L. Archer,F Charbonneau,Eric A. Cohen,M Curtis,C.E. Buller,F O Mendelsohn,Nabil Dib,P Page,J Ducas,S Plante,J Sullivan,Jennifer Macko,Camilla Sandvad Rasmussen,Paul D. Kessler,Henrik S. Rasmussen +19 more
TL;DR: Administration of AdVEGF121 by direct intramyocardial injections resulted in objective improvement in exercise-induced ischemia in patients with refractory ischemic heart disease.
Journal Article
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
John Nemunaitis,C Poole,John N. Primrose,A Rosemurgy,J Malfetano,P Brown,A Berrington,A Cornish,Kevin Lynch,Henrik S. Rasmussen,D Kerr,David Cox,A Millar +12 more
TL;DR: This combined analysis investigated the effect of marimastat, a specific inhibitor of matrix metalloproteinases, on markers of tumor progression measured in patients with advanced cancer by defining the tolerability and biological activity of the drug and establishing an appropriate dose range for use in Phase III trials.
Journal ArticleDOI
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Neil Senzer,Sridhar Mani,Alexander Rosemurgy,John Nemunaitis,Casey Cunningham,Chandan Guha,Natalia Bayol,Michelle Gillen,Karen Chu,Camilla Sandvad Rasmussen,Henrik S. Rasmussen,D. Kufe,Ralph R. Weichselbaum,Nader Hanna +13 more
TL;DR: The integrated treatment of TNFerade and radiation was well tolerated in patients with predominantly prior treatment-refractory solid tumors, and a differential response between lesions treated with T NFerade + radiation compared with radiation only was observed.
Journal ArticleDOI
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Ben-Gary Harvey,Jaman Maroni,Kelley A. O'Donoghue,Karen W. Chu,Jolene C. Muscat,Allison L. Pippo,Connie E. Wright,Charleen Hollmann,Juan P. Wisnivesky,Paul D. Kessler,Henrik S. Rasmussen,Todd K. Rosengart,Ronald G. Crystal +12 more
TL;DR: Observations are consistent with the concept that local administration of low and intermediate doses of Ad vectors appears to be well tolerated, including incidence of death or development of malignancy.